Ulcerative colitis (UC) is a chronic intermittent relapsing disorder of the large intestine and rectum. Treatment typically begins with conventional agents (e.g., 5-ASAs), which are often effective for patients with mild to moderate disease, but then progresses to more-potent drugs, such as immunosuppressants and/or biologics, as needed. Among the biologics, TNF-alpha inhibitors (Janssen’s Remicade and AbbVie’s Humira) and the cell adhesion molecule (CAM) inhibitor (Takeda’s Entyvio) are the mainstays of treatment. However, therapies such as Pfizer’s Xeljanz / Xeljanz XR, the first approved oral Jak inhibitor, and Janssen’s Stelara are increasing the competition in the market, among later-line targeted therapies.
Markets covered: United States
Key companies: Janssen, AbbVie, Takeda, Pfizer, BMS
Key drugs: Humira, Remicade, Entyvio, Stelara, Simponi, Xeljanz / Xeljanz XR, Zeposia, biosimilar infliximab, aminosalicylates, immunosuppressants
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.